同时，支持关键技术攻关。在广西科技计划项目申报指南中设置医药、医疗器械相关方向，支持珍 稀濒危中药资源繁育、仿生、替代技术研发及中药材育种攻关。支持北部湾特色优势海洋中药资源普 查、开发与技术攻关，建设海洋生物医药种质资源库。 支持中药大品种二次开发，新靶点、新机制、 新结构研究，以及高端医疗器械与医用材料研制。支持突破基于人工智能与生物模型驱动的高通量筛选 和药物设计、高附加值化学原料药绿色合成等关键技术。鼓励企业开展仿制药质量和疗效一致性评价， 对符合豁免生物等效性试验原则的，按品种类型给予不超过150万元支持；对需开展体内生物等效性试 验的，按品种类型给予不超过400万元支持。 日前，自治区政府办公厅印发《关于推动广西生物医药产业高质量发展的若干政策措施》，旨在进 一步提升产业特色化、集聚化与智能化水平，打造广西特色资源型医药、生物制造与大健康产业链供应 链，建设面向东盟的重要生物医药制造基地，推动产业高质量发展。 在促进产业化发展方面，对新取得国家药品或医疗器械注册批件并落地生产的企业，按注册分类和 产业化规模给予支持。其中，1类创新药不超过3000万元，2类改良型新药不超过1000万元，3类化学 药 ...

Group 1 - The Chinese government is supporting the high-quality development of innovative drugs by providing up to 10 million yuan in funding for eligible projects, including first-class innovative drugs, second-class improved new drugs, and biosimilars [1] - Chinese pharmaceutical companies are transitioning from raw material producers to innovative drug manufacturers, with their share in global drug research and development nearing 30%, while the share of US companies has decreased to approximately 48% [4] - The number of Chinese innovative drugs included in global conference abstracts has reached a record high this year, indicating a growing recognition of China's contributions to drug development [4] Group 2 - In the first half of this year, US and Chinese pharmaceutical companies completed 14 licensing deals worth $18.3 billion, highlighting increasing collaboration between the two markets [4] - The expiration of patents for blockbuster drugs before 2030 is creating opportunities for collaboration between US and Chinese pharmaceutical companies, as US firms need to replenish their drug development pipelines [4] - The high costs associated with drug development in the US present challenges, further opening the door for partnerships with Chinese companies [4]